For the quarter ending 2026-03-31, AUPH had -$39,205K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 34,355 | 210,794 | 31,551 | 44,857 |
| Deferred income tax | 9,277 | -176,194 | - | - |
| Share-based compensation | -866 | 6,728 | 5,919 | 2,031 |
| Amortization and depreciation | 4,816 | 4,864 | 4,865 | 9,720 |
| Foreign exchange (gain) loss on revaluation of monoplant finance lease liability | 416 | -367 | -53 | -9,265 |
| Net amortization of premiums and discounts on investments | 2,319 | 2,335 | 2,625 | 5,219 |
| Non-cash write-down of inventory | - | 0 | - | - |
| Other, net | -581 | 5,052 | -720 | -4,132 |
| Accounts receivable, net | 7,721 | 10,726 | -9,363 | 3,547 |
| Inventory | 720 | 897 | -1,710 | 7,275 |
| Prepaid expenses and other current assets | -950 | -4,582 | 4,166 | -5,106 |
| Other noncurrent operating assets | - | 0 | 0 | -730 |
| Accounts payable | -652 | 1,099 | -1,098 | -1,875 |
| Accrued expenses and other liabilities | -5,592 | 13,122 | -641 | -17,136 |
| Deferred revenue | 1,081 | -482 | -997 | 5,147 |
| Operating lease liabilities | -214 | -202 | -205 | -395 |
| Cash flows from operating activities | 32,560 | 45,668 | 44,449 | 45,541 |
| Proceeds from the sale and maturities of investments | 109,000 | 145,349 | 93,500 | 255,285 |
| Purchases of investments | 127,041 | 182,032 | 107,207 | 237,411 |
| Upfront lease payments | - | 0 | 0 | - |
| Purchases of property, equipment and intangible assets | 39 | 72 | 65 | 115 |
| Cash flows from investing activities | -18,080 | -36,755 | -13,772 | 17,759 |
| Purchase of common shares under share repurchase plan | 36,165 | 0 | 8,671 | 89,485 |
| Payments of principal portion of monoplant finance lease liability | 3,653 | 3,487 | 3,448 | 6,201 |
| Proceeds from issuance of common shares for equity awards | 713 | 1,607 | 1,993 | 10,590 |
| Proceeds from issuance of common shares under espp | - | 355 | 0 | 401 |
| Tax withholding payments related to net settlements of equity awards | 14,580 | 364 | 364 | 9,036 |
| Cash flows from financing activities | -53,685 | -1,889 | -10,490 | -93,731 |
| Net decrease in cash, cash equivalents and restricted cash | -39,205 | 7,024 | 20,187 | -30,431 |
| Cash, cash equivalents and restricted cash, beginning of the period | 80,213 | 73,189 | 83,433 | - |
| Cash, cash equivalents and restricted cash, end of the period | 41,008 | 80,213 | 73,189 | - |
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)